WO2025229631 - A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER
National phase entry is expected:
Publication Number
WO/2025/229631
Publication Date
06.11.2025
International Application No.
PCT/IB2025/054668
International Filing Date
05.05.2025
Title **
[English]
A CD47-SIRPα BLOCKING AGENT FOR THE TREATMENT OF CANCER
[French]
AGENT BLOQUANT CD47-SIRPα POUR LE TRAITEMENT DU CANCER
Applicants **
AURIGENE ONCOLOGY LIMITED
Inventors
KUMAR, Akhil
KRISHNAPPA, Manjunath
KUMAR TIWARI, Nirbhay
Priority Data
202441035250
03.05.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4621 | |
| EPO | Filing, Examination, Granting | 81998 | |
| Japan | Filing, Examination, Granting | 4593 | |
| South Korea | Filing, Examination, Granting | 6865 | |
| USA | Filing, Examination, Granting | 20540 |
Total:
118,617
Contact Us
Abstract[English]
The present present disclosure relates to a CD47-SIRPα blocking agent of formula (I) stereoisomers thereof, and pharmaceutically acceptable salts, solvates, amides and esters of the compound of formula (I) and stereoisomer thereof for use in a method of treating or delaying progression of a disease or a disorder mediated by CD47-SIRPα pathway in a human subject suffering from said disease, such as cancer.[French]
La présente invention concerne un agent bloquant CD47-SIRPα de formule (I), des stéréoisomères de celui-ci, et des sels, solvates, amides et esters pharmaceutiquement acceptables du composé de formule (I) et du stéréoisomère correspondant, destinés à être utilisés dans une méthode pour traiter ou retarder l'évolution d'une maladie ou d'un trouble médié par la voie CD47-SIRPα chez un sujet humain souffrant de ladite maladie, telle que le cancer.